Severe Thrombocytopenia Due to Repaglinide in a Patient With Type 2 Diabetes

Repaglinide is an insulin secretagogue with a rapid onset and short duration of action. Several studies have proposed repaglinide to be a safe and effective treatment for patients, including elderly people with type 2 diabetes (1–3). Here we report a case subject with type 2 diabetes who showed severe thrombocytopenia due to repaglinide. A 71-year-old man was referred and admitted to our hospital due to poor glycemic control in July 2012. His plasma glucose (350 mg/dL) and HbA1c (7.6%) levels were significantly elevated. The intensive insulin therapy promptly ameliorated his blood glucose, which was 91–151 mg/dL, by using 6 and 8 units of insulin glulisine before …